AZ13381758, a small-molecule inhibitor of CXCR2, was able to reduce metastasis and substantially improved life span in a pancreatic ductal adenocarcinoma model, when combined with gemcitabine [121], while in a prostate cancer model, CXCR2 inhibition by SB265610 was able to limit tumor growth by decreasing myeloid cell infiltration and enhancing Docetaxel-induced senescence [122]. Here, CXCR2 is linked to prostate carcinoma.